MedTrace Logo

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

NCT02602600 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2018-07-11

No results posted yet for this study

Summary

The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.

Conditions

  • Microvascular Angina

Interventions

DRUG

Liraglutide

* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks. * Weight maintenance diet for 2 weeks

Sponsors & Collaborators

  • Eva Prescott

    lead OTHER

Principal Investigators

  • Eva IB Prescott, MD, DMSc · Bispebjerg Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-19
Primary Completion
2017-04-18
Completion
2017-04-18

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602600 on ClinicalTrials.gov